Last reviewed · How we verify
Magnesium Orthophosphate (magnesium phosphate)
Magnesium Orthophosphate (generic name: magnesium phosphate) is a magnesium phosphate drug. It is currently in unknown development.
Magnesium Orthophosphate works by binding to phosphate groups in the body, potentially influencing various cellular processes.
Magnesium Orthophosphate, also known as magnesium phosphate, is a small molecule drug in the magnesium phosphate class. Its mechanism of action and approved indications are not well-documented, and it is unclear if it is FDA-approved or commercially available. As a result, there is limited information available on its safety profile, bioavailability, or half-life. Further research is needed to determine its potential therapeutic applications and commercial status. Without more information, it is difficult to provide a comprehensive summary of this compound.
At a glance
| Generic name | magnesium phosphate |
|---|---|
| Drug class | magnesium phosphate |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells have locks that need a specific key to open. Magnesium Orthophosphate is like a key that fits into these locks, allowing the cell to function properly. This can help to regulate various bodily functions, but more research is needed to understand exactly how it works.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Effects of a Microalgae Extract Dietary Supplement on Gut Health, Anxiety, and Immune Function (NA)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy (NA)
- Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease (PHASE2)
- Natural Bioactive Gel for Peri-Implantitis (NA)
- A Study to Assess Efficacy of Supporting Properties and Safety of ARTNEO in Patients With Knee Osteoarthritis (NA)
- Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnesium Orthophosphate CI brief — competitive landscape report
- Magnesium Orthophosphate updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Magnesium Orthophosphate
What is Magnesium Orthophosphate?
How does Magnesium Orthophosphate work?
What is the generic name of Magnesium Orthophosphate?
What drug class is Magnesium Orthophosphate in?
What development phase is Magnesium Orthophosphate in?
Related
- Drug class: All magnesium phosphate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing